If the immune checkpoint VISTA inhibitor is combined at this time, it will improve the anti-tumor efficacy, and this benefit can only occur when the CMNa sensitization radiotherapy is combined with the VISTA inhibitor treatment at the same time. The gene discussed is VSIR; the disease is neoplasm.